Skip To Main Content
Barbara Barun on Muck Rack

Barbara Barun

As seen in: Multiple Sclerosis and Related Disorders
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immunoglobulin Dynamics and Infection Risk with Ofatumumab versus Ocrelizumab in Multiple Sclerosis

|
By Laura Zanetti, Ivan Adamec, Barbara Barun
| Multiple Sclerosis and Related Disorders Verified
Keywords Anti-CD20 therapy Hypogammaglobulinemia Immunoglobulins Infection risk Get full text access Log in, subscribe or purchase for full access. References 1. de Sèze, J. ∙ Maillart, E. ∙ Gueguen, A. ... Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic Front Immunol. 2023; 14, 1004795 2. Furst, DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum. 2009; 39:18-29 3. Vanoverschelde, A. ∙ Khan, S.R. ∙ Virgil, D. ...
Open in Who Shared Issue with article?

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: A Multicenter Cohort Study

|
By Barbara Barun, Ivan Adamec, Ivan Martínez, Iván Martínez, Mario Habek
| Multiple Sclerosis and Related Disorders Verified
Keywords relapsing multiple sclerosis ofatumumab effectiveness safety real-world studies Get full text access Log in, subscribe or purchase for full access. References 1. Goldschmidt, C. ∙ McGinley, MP. Advances in the Treatment of Multiple Sclerosis Neurol Clin. 2021; 39:21-33 2. Hauser, S.L. ∙ Bar-Or, A. ∙ Cohen, J.A. ... ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis N Engl J Med. 2020; 383:546-557 3. Gärtner, J. ∙ Hauser, S.L. ∙ Bar-Or, A. ...
Open in Who Shared Issue with article?

The impact of national policies on reimbursement of disease-modifying therapies for multiple sclerosis on disease outcomes: Slovenia versus Croatia

|
By Ivan Adamec, Barbara Barun, Mario Habek, Sarah Gomezelj
| Multiple Sclerosis and Related Disorders Verified
Keywords Multiple sclerosis disease-modifying therapies reimbursement national Get full text access Log in, subscribe or purchase for full access. Data availability The data supporting this study’s findings are available from the corresponding author upon reasonable request. References 1. Confavreux, C. ∙ Vukusic, S. Natural history of multiple sclerosis: a unifying concept Brain. 2006; 129:606-616 2. Cree, B.A. ∙ Gourraud, P.A. ∙ Oksenberg, J.R. ...
Open in Who Shared Issue with article?
See all 10 articles